Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cereno Scientific releases Insights Videos Season 3 Episode 1–4 with Sten R. Sörensen, CEO, Cereno Scientific

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that episodes 1- 4 of Season 3 in the Insights Video Series has been released. In the videos, recorded at the Pulmonary Vascular Research Institute (PVRI) Annual Congress 2024, CEO Sten R. Sörensen highlights the remarkable early signs of efficacy in Cereno Scientific’s Phase II study with candidate drug CS1 in patients with PAH, the importance of the “Compassionate Use”-approval for CS1 by the FDA, the potential of HDAC inhibition by CS1 and

Year-end bulletin Pharmacolog 2023

Press release: Uppsala, February 16, 2024 Pharmacolog i Uppsala AB (publ) year-end bulletin for the period January - December 2023 is now available on the company's website  and is attached as a pdf.Fourth quarter October 1 - December 31, 2023 · The Group's net sales for the fourth quarter amounted to KSEK 2 567 (1 785). · Operating profit for the quarter amounted to KSEK -4,159 (-6,763). · Net earnings per share for the quarter were SEK -0.06 (-0.36) before dilution and SEK -0.03 (-0.31) after dilution. The

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseFebruary 16, 2024 at 9.30 am EETRepurchase of Outokumpu’s own shares On February 15, 2024, Outokumpu has completed repurchases of its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |17,167 |4.1134

Year-end report 2023: Scientific and regulatory progress generating international interest

Fourth quarter January-December · Net sales reached SEK · Net sales reached SEK 50.9 (48.9)15.8 (16.6) million. million. · The operating result · The operating result totaled SEK -48.1 (totaled SEK -13.8 (-21.6) -68.2) million.million. · Earnings per share, basic and diluted, · Earnings per share, basic wereand diluted, were SEK -0.30 (-0.44).SEK -0.09 (-0.14). · Cash flow from operating activities for · Cash flow from operating the period totaled SEK -40.3 (-65.4)

Elicera invites to investor meetings on February 28[th] and 29[th] 2024

In connection with the upcoming rights issue in Elicera Therapeutics AB (publ) ("Elicera" or "the Company"), the Company invites shareholders and the public to an investor meeting in Stockholm and a digital investor meeting.Elicera's CEO, Jamal El-Mosleh, will present the Company on two occasions. The first occasion is on Wednesday, February 28th, at 4:00 PM and will be held digitally via Microsoft Teams. The second occasion is on Thursday, February 29th, at 12:00 PM and will be held at Mangold Fondkommission’s premises at Nybrogatan 55, where lunch will also be provided. Do note that both

BioStock: Alligator's CEO comments on restructuring plan

Alligator Bioscience is coming off a high after reaching the primary endpoint in the OPTIMIZE-1 phase II trial with lead candidate mitazalimab. However, together with their year-end report, Alligator announced a restructuring and cost-cutting plan. Alligator’s CEO Søren Bregenholt stopped by the BioStock studio to tells us more.Watch the interview with Søren Bregenholt at BioStock.se https://www.biostock.se/en/2024/02/alligators-ceo-comments-on-restructuring-plan/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Share-based payments related to Metso’s long-term incentive plans

Metso Corporation’s stock exchange release on February 16, 2024, at 9:15 a.m. EETMetso’s Board of Directors has decided to convey maximum total of 1,460,759 of the company’s treasury shares without consideration to 177 key persons and executives in accordance with the terms and conditions of the Performance Share Plan 2021-2023 (PSP 2021-2023) and Restricted Share Plan 2021-2023 (RSP 2021-2023). The directed share issue is based on an authorization given by the Annual General Meeting held on May 3, 2023. The conveyance of shares will be executed on two dates depending on the plan:

Notice to Exel Composites Plc’s Annual General Meeting 2024

EXEL COMPOSITES PLC     STOCK EXCHANGE RELEASE       16.2.2024 at 09:15 EETNotice is given to the shareholders of Exel Composites Plc to the Annual General Meeting of Shareholders to be held on Tuesday 26 March 2024 at 10:00 EET at Scandic Marina Congress Center at the address Katajanokanlaituri 6, Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 9:30 EET at the meeting venue. Shareholders can also exercise their right to vote by voting in advance. Instructions for advance voting are presented in this

Notice to the Annual General Meeting of Metso Corporation

Metso Corporation’s stock exchange release on February 16, 2024, at 9:05 a.m. EETNotice to the Annual General Meeting of Metso Corporation Notice is given to the shareholders of Metso Corporation (“Metso” or the “Company”) to the Annual General Meeting (the “General Meeting”) to be held on Thursday, April 25, 2024, at 2.00 p.m. (EEST) at Messukeskus (Siipi entrance) at the address Rautatieläisenkatu 3, 00520 Helsinki, Finland. The reception of attendees who have registered for the General Meeting and the distribution of voting tickets will commence at the meeting venue at 1.00 p.m. (EEST)

Viking Line Abp: Financial Statement Release 2023

Viking Line Abp               FINANCIAL STATEMENT RELEASE           16.02.2024, 9.00 AM Viking Line posts historically strong earnings   JANUARY-DECEMBER 2023  (compared to January–December 2022)  · Sales amounted to EUR 491.4 M (EUR 494.7 M). · Other operating revenue was EUR 9.1 M (EUR 24.1 M). · Operating income totalled EUR 55.0 M (EUR 38.3 M). · Net financial items were EUR -9.6 M (EUR -10.3 M). · Income before taxes totalled EUR 45.4 M (EUR 28.0 M). · Income after taxes totalled EUR 36.3 M (EUR 22.7 M). · The Board of Directors proposes a dividend of

Polymer Factory Sweden AB (publ) year-end report, Q4 2023

The period in summary Fourth quarter, October-December 2023 · SpheriCal® ESI was launched as commercially available · Representatives of the Company participated in the second in-person consortium meeting for the Nano-SHIELD project Full year, January-December 2023 · The Board of Directors resolved on a share issue, with subsequent approval by the EGM · The Company raised approx. SEK 6,1 million* through a rights issue of shares · The first instalment of the EDF grant was paid, amounting to approx. SEK 1,8 million** · The Company exhibited and presented at the

New EVP Finance and CFO at Orkla ASA

Arve Regland has been appointed new EVP Finance and CFO at Orkla ASA and will take up the position on 1 June 2024.Arve Regland comes from the investment company Melesio. From 2019 to 2023, he served as CFO at Fredensborg and its subsidiary Heimstaden. From 2014 to 2019, he was employed at Entra, first as CFO and for the last four years as CEO. Mr Regland has also worked at ABG Sundal Collier and Arthur Andersen/Ernst & Young. He has an M.Sc. Business (siviløkonom) from BI Norwegian Business School and an MBA (Master of Professional Accountancy) from the Norwegian School of Economics (NHH).

Year-End Report 1 jan–31 dec 2023

Strong cash flow and increased profitabilityFourth quarter highlights · Revenue decreased by -6.8 per cent to MSEK 2,538 (2,723). Organic growth was -7.5 per cent. · Gross margin increased to 43.4 per cent (41.4). · Adjusted EBITA increased by 3 per cent to MSEK 308 (298), corresponding to an adjusted EBITA margin of 12.1 per cent (10.9). · Operating profit increased to MSEK 278 (268) and the operating margin was 11.0 per cent (9.8). Operating profit was charged with items affecting comparability of MSEK -16 (-15). · Profit amounted to MSEK 192 (194). · Earnings per

Notice convening the Annual General Meeting of AB Electrolux

The shareholders of AB Electrolux, reg. no. 556009-4178 (the “Company”), are hereby given notice of the Annual General Meeting to be held on Wednesday, March 27, 2024, at 4.00 p.m. (CET) at Nalen, Regeringsgatan 74 in Stockholm, Sweden. Admission and registration will commence at 3.15 p.m. (CET).The Board of Directors has decided that the shareholders shall have the possibility to exercise their voting rights by postal voting before the Annual General Meeting, as instructed below. The Annual General Meeting will be webcasted live via Electrolux Group’s website, www.electroluxgroup.com/

United Bankers Plc’s Financial Statements Bulletin 2023: Record profit supported by new strategic funds

United Bankers Plc 16 February 2024 at 9:00 EET United Bankers Plc’s Financial Statements Bulletin 2023: Record profit supported by new strategic funds This stock exchange release is a summary of the United Bankers’ Financial Statements Bulletin 1 January – 31 December 2023. The complete Financial Statements Bulletin with tables is attached to this release and is also available on the company’s website at www.unitedbankers.fi. The figures in this release are unaudited. January-December 2023 in brief · The Group’s revenue (income from operations) in the financial period

Stille AB: Year-End Report 2023

Stille AB (publ) today presents the report for the fourth quarter and full fiscal year 2023. ”Strong finish to the year with solid sales growth, enhanced profitability and the strategic acquisition of Fehling Instruments”, summarizes President and CEO Torbjörn Sköld in the year-end report.Revenue increased in the fourth quarter by 25.0 percent to 77.3 MSEK (61.8) with strong growth from both business units. “I am pleased to note that our growth momentum remains strong in the fourth quarter, and we continue to deliver on our growth strategy. 2023 marked a significant milestone for Stille.”,

ContextVision publishes Webcast for Q4 2023

Watch CEO Gerald Pötzsch and CFO Richard Hallström present ContextVision's highlights from Q4 2023 along the financials for the quarter and full year.  The Webcast is available on ContextVision's website following the link below: https://www.contextvision.com/investors/webcast/ For more details, contact ContextVision's CFO, Richard Hallström at richard.hallstrom@contextvision.com or visit our official website at www.contextvision.com. About ContextVisionContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the

Changes to Intrum’s Group Management Team

Emil Folkesson has been appointed interim CFO of Intrum. Anders Blomqvist, who took on the interim CFO role in December, remains as Senior Consultant reporting directly to CEO Andrés Rubio. The changes take effect from 16 February. In addition, new regional directors have been named for North and Middle Europe.“Since Anders Blomqvist joined Intrum as interim CFO mid-December, the focus has been to close and announce the fourth quarter of 2023 and to finalise the asset sale to Cerberus which we announced 23 January”, says Andrés Rubio, President & CEO of Intrum. “As we now have these two

SaltX Technology Holding AB Year-end Report 2023

SaltX Technology is a Swedish Greentech company that develops and markets sustainable technology that benefits customers, the climate, and society. Today, the company issued its Year-end Report for 2023.“We are at the beginning of industrialization and commercialization, where we now level up to meet the growing demand for our electrification technology. We aim to become an industrial supplier significantly reducing global carbon dioxide emissions." - Carl-Johan Linér, CEO SaltX  Presentation of the Year-end Report The report is presented in a video interview where SaltX CEO Carl-

Year-end report 2023

Strong company and positive outlookJohn Mattson’s net operating income per share increased 10% during 2023, while EBIT increased 14%. This despite a year of persistent high inflation, non-recurring costs of SEK 3 million and a smaller property portfolio as a result of divestments in 2022 and 2023. In comparable holdings, net operating income increased 20% and EBIT increased 27%.The surplus ratio amounted to 72%, which is a record high for the company. This was primarily the result of the efficiency and cost-savings programme launched in autumn 2022 and completed in 2023. As a result of

RANPLAN GROUP AB – Interim Report July - Dec 2023

2024-02-16 08:00 CET The period in summary Second half of 2023 (second half of 2022)         Total income amounted to SEK 15.4 million (15.1 million)1       Net sales amounted to SEK 9.4 million (9.7 million)       Operating income amounted to SEK -9.6 million (-12.6 million)       Net income amounted to SEK -11.3 million (-13.0 million)       Earnings per share amounted to SEK -0.36 (-0.43)       Cash at the end of the period amounted to SEK 1.5 million (5.1 million)   Full year of 2023 (Full year of 2022)         Total income amounted to SEK

Oneflow year-end report 2023: Breaking old records is becoming a habit

Press release16 February 2024 Oneflow publishes its year-end report for January–December 2023: October–December 2023 (compared to the same period last year) · Net sales increased 39.5% to MSEK 28.4 (20.4). Share of Net sales outside Sweden increased to 33% (28) with paying users in 40 countries. · EBIT was MSEK -26.5 (-24.4), with an EBIT margin of -93% (-120). · Net income for the period amounted to -26.3 (-24.0). · Basic earnings per share amounted to SEK -1.05 (-0.95) and diluted to SEK -1.05 (-0.95). · Total ARR YoY increased 42.7% to MSEK 129.3 (90.6). Net New

There are no items matching the current filter
There are no more items matching the current filter
Back to top